HypertensionPhase 2VISTANCT07447206
Vascular Intervention Strategies Trial for Alzheimer's
A Phase 2 study testing Angiotensin Receptor Blockers (ARBs) and Hydrophilic Statins or Non-Statin Alternative in people with Hypertension and Hypercholesterolemia, run by University of Southern California at 1 site in United States.
Trial summary
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. Read more about this study
- Who is it for?
- Ages 50 to 75 years
- Conditions the study is for
- Hypertension, Hypercholesterolemia, Dementia Risk Factors
- What is being tested?
- Angiotensin Receptor Blockers (ARBs) and Hydrophilic Statins or Non-Statin Alternative
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- May 2026to Jun 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- APOE ε4 carrier (homozygote or heterozygote)
- LDL-C of 100-250 mg/dL
- Systolic blood Pressure (SBP) 130-180 mm Hg
- Age 50-75 years
- Fluency in English
- No dementia based on medical record review
- Male or post-menopausal female
Who cannot join
- One minute standing SBP < 110 mm Hg
- Arm circumference prevents from accurate BP measurement with use of available devices
- Lost weight of > 10% unintendedly (within the past 6 months),
- Contraindications to blood pressure and cholesterol lowering medications
- Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
- Evidence of dementia based on medical record review
Show all 18Show fewer
- Living in a skilled nursing or rehabilitation facility
- Receiving palliative or hospice care
- Bipolar illness or schizophrenia
- Drug or alcohol disorder
- Receiving chronic opioid therapy
- Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
- Severe loss of visual, hearing or communication ability
- Organ transplant
- History of stroke, symptomatic HF or left ventricular ejection fraction < 35%
- ESRD or eGFR < 20 ml/min /1.73m2
- Does not consent to be contacted or to have their medical record reviewed for research purposes
- Concurrent participation in another clinical trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Clinical Sciences Building (CSC)
Los Angeles, California, 90033
About this study
Official title: Vascular Intervention Strategies Trial for Alzheimer's (VISTA)
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
- Conditions
- Hypertension, Hypercholesterolemia, Dementia Risk Factors
- Being tested
- Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative
- Keywords
- APOE ε4 carriers, Dementia risk, Hypertension, Hypercholesterolemia, Vascular risk factors, Pharmacist-led intervention, Feasibility study
- Medical subject headings
- Hypertension, Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Angiotensin Receptor Blockers (ARBs)Drug
Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).
Hydrophilic Statins or Non-Statin AlternativeDrug
Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.
| Study group | Role | What they receive |
|---|---|---|
| Pharmacist-Led Vascular Risk Factor Management | Experimental | Participants receive pharmacist-led management of hypertension and hypercholesterolemia using angiotensin receptor blockers and hydrophilic statins (or non-statin alternatives) over six months. Receives: Drug: Angiotensin Receptor Blockers (ARBs); Drug: Hydrophilic Statins or Non-Statin Alternative |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood Pressure Control
Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.
Measured: Baseline to 6 months
Secondary outcomes (2)
Lipid Level Changes
Change in LDL cholesterol (mg/dL) from baseline to 6 months.
Measured: Baseline to 6 months
Feasibility Metrics
adherence to prescribed medications (%).
Measured: Study duration (6 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study startMay 2026 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hussein Yassine, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07447206
- Sponsor's protocol ID
- HS-24-00340
- Other IDs
- PG1040967
- Acronym
- VISTA
- Status last verified
- Apr 2026
- First submitted
- 25 Feb 2026
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vascular Intervention Strategies Trial for Alzheimer's (VISTA)
- ClinicalTrials.gov ID
- NCT07447206
- Acronym / sponsor ID
- VISTA / HS-24-00340
- Conditions
- Hypertension, Hypercholesterolemia, Dementia Risk Factors
- Keywords
- APOE ε4 carriers, Dementia risk, Hypertension, Hypercholesterolemia, Vascular risk factors, Pharmacist-led intervention, Feasibility study
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Study start
- May 2026 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 3 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pharmacist-Led Vascular Risk Factor Management | Experimental | Drug: Angiotensin Receptor Blockers (ARBs), Drug: Hydrophilic Statins or Non-Statin AlternativeParticipants receive pharmacist-led management of hypertension and hypercholesterolemia using angiotensin receptor blockers and hydrophilic statins (or non-statin alternatives) over six months. |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- APOE ε4 carrier (homozygote or heterozygote)
- LDL-C of 100-250 mg/dL
- Systolic blood Pressure (SBP) 130-180 mm Hg
- Age 50-75 years
- Fluency in English
Key exclusion criteria (18 listed)
- One minute standing SBP < 110 mm Hg
- Arm circumference prevents from accurate BP measurement with use of available devices
- Lost weight of > 10% unintendedly (within the past 6 months),
- Contraindications to blood pressure and cholesterol lowering medications
- Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Angiotensin Receptor Blockers (ARBs)Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs). | Drug | Pharmacist-Led Vascular Risk Factor Management |
| Hydrophilic Statins or Non-Statin AlternativeParticipants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate. | Drug | Pharmacist-Led Vascular Risk Factor Management |
Primary outcome
Blood Pressure Control
Time frame: Baseline to 6 months
Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.
2 secondary outcomes
Lipid Level Changes
Time frame: Baseline to 6 months
Feasibility Metrics
Time frame: Study duration (6 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Angiotensin Receptor Blockers (ARBs) and Hydrophilic Statins or Non-Statin Alternative in people with Hypertension and Hypercholesterolemia, run by University of Southern California at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hussein Yassine, MD ((323) 442-0272, hyassine@usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood Pressure Control (time frame: Baseline to 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.